Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.000427 | uM | 7510.074 | 1.0307 | 1.0777 | 0.7920 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.000427 | uM | 7510.074 | 1.0307 | 1.0777 | 0.7920 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.00213 | uM | 7510.074 | 1.0094 | 1.0238 | 0.7920 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.00213 | uM | 7510.074 | 1.0094 | 1.0238 | 0.7920 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.0107 | uM | 7510.074 | 1.0732 | 1.1865 | 0.7920 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.0107 | uM | 7510.074 | 1.0732 | 1.1865 | 0.7920 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.0533 | uM | 7510.074 | 1.0188 | 1.0476 | 0.7920 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.0533 | uM | 7510.074 | 1.0188 | 1.0476 | 0.7920 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.267 | uM | 7510.074 | 0.3202 | -0.5251 | 0.7920 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.267 | uM | 7510.074 | 0.3202 | -0.5251 | 0.7920 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 1.33 | uM | 7510.074 | 0.1825 | -0.7664 | 0.7920 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 1.33 | uM | 7510.074 | 0.1825 | -0.7664 | 0.7920 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 6.67 | uM | 7510.074 | 0.1182 | -0.8651 | 0.7920 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 6.67 | uM | 7510.074 | 0.1182 | -0.8651 | 0.7920 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 33.3 | uM | 7510.074 | 0.0403 | -0.9653 | 0.7920 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 33.3 | uM | 7510.074 | 0.0403 | -0.9653 | 0.7920 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 167 | uM | 7510.074 | 0.0428 | -0.9626 | 0.7920 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 167 | uM | 7510.074 | 0.0428 | -0.9626 | 0.7920 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.000427 | uM | 7511.074 | 0.9908 | 0.9853 | 1.2617 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.000427 | uM | 7511.074 | 0.9908 | 0.9853 | 1.2617 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.00213 | uM | 7511.074 | 0.9891 | 0.9828 | 1.2617 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.00213 | uM | 7511.074 | 0.9891 | 0.9828 | 1.2617 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.0107 | uM | 7511.074 | 0.9754 | 0.9609 | 1.2617 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.0107 | uM | 7511.074 | 0.9754 | 0.9609 | 1.2617 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.0533 | uM | 7511.074 | 0.8900 | 0.8235 | 1.2617 |